This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2013 Dec 1;12(23):3581-2.

doi: 10.4161/cc.26824. Epub 2013 Oct 21.

Gfi1: a unique controller of T(reg) cells

Lewis Zhichang Shi¹, Hongbo Chi

Affiliations

PMID: 24131921
PMCID: PMC3903705
DOI: 10.4161/cc.26824

Editorial

Gfi1: a unique controller of T(reg) cells

Lewis Zhichang Shi et al. Cell Cycle. 2013.

. 2013 Dec 1;12(23):3581-2.

doi: 10.4161/cc.26824. Epub 2013 Oct 21.

Authors

Lewis Zhichang Shi¹, Hongbo Chi

Affiliation

¹ Department of Immunology; St. Jude Children's Research Hospital; Memphis, TN USA.

PMID: 24131921
PMCID: PMC3903705
DOI: 10.4161/cc.26824

No abstract available

Keywords: CD103; CD73; Foxp3; Gfi1; IL-2; Treg development; tumor immunity.

PubMed Disclaimer

Figures

None — Figure 1. Control of Foxp3⁺ nT_reg cells and antitumor immunity by Gfi1. Loss of Gfi1 in conventional T cells (T_conv) leads to increased secretion of IL-2, which promotes nT_reg cell expansion in the thymus and periphery. Gfi1 deletion also upregulates T_reg effector molecules CD103 and CD73. Collectively, Gfi1 deficiency in T cells dampens antitumor immunity. ↑, increased expression or cellularity.

See this image and copyright information in PMC

Comment on

Shi LZ, et al. Proc Natl Acad Sci U S A. 2013;110:E3198–205. doi: 10.1073/pnas.1300950110.

Similar articles

GFI1/HDAC1-axis differentially regulates immunosuppressive CD73 in human tumor-associated FOXP3⁺ Th17 and inflammation-linked Th17 cells.
Roy D, Bose S, Pati S, Guin A, Banerjee K, Saha S, Singhal AK, Chakraborty J, Sarkar DK, Sa G. Roy D, et al. Eur J Immunol. 2021 May;51(5):1206-1217. doi: 10.1002/eji.202048892. Epub 2021 Feb 17. Eur J Immunol. 2021. PMID: 33555624
In vivo-activated CD103+ Foxp3+ Tregs: of men and mice.
Rötzschke O, Borsellino G, Battistini L, Falk K, Kleinewietfeld M. Rötzschke O, et al. Blood. 2009 Feb 26;113(9):2119-20; author reply 2120. doi: 10.1182/blood-2008-11-188847. Blood. 2009. PMID: 19246567 No abstract available.
Down-regulation of Gfi-1 expression by TGF-beta is important for differentiation of Th17 and CD103+ inducible regulatory T cells.
Zhu J, Davidson TS, Wei G, Jankovic D, Cui K, Schones DE, Guo L, Zhao K, Shevach EM, Paul WE. Zhu J, et al. J Exp Med. 2009 Feb 16;206(2):329-41. doi: 10.1084/jem.20081666. Epub 2009 Feb 2. J Exp Med. 2009. PMID: 19188499 Free PMC article.
Targeting adenosine and regulatory T cells in cancer immunotherapy.
Churov A, Zhulai G. Churov A, et al. Hum Immunol. 2021 Apr;82(4):270-278. doi: 10.1016/j.humimm.2020.12.005. Epub 2021 Feb 18. Hum Immunol. 2021. PMID: 33610376 Review.
Thymic regulatory T cell development: role of signalling pathways and transcription factors.
Engel M, Sidwell T, Vasanthakumar A, Grigoriadis G, Banerjee A. Engel M, et al. Clin Dev Immunol. 2013;2013:617595. doi: 10.1155/2013/617595. Epub 2013 Sep 26. Clin Dev Immunol. 2013. PMID: 24187564 Free PMC article. Review.

See all similar articles

Cited by

Gfi1 controls the formation of effector-like CD8⁺ T cells during chronic infection and cancer.
Ojo OA, Shen H, Ingram JT, Bonner JA, Welner RS, Lacaud G, Zajac AJ, Shi LZ. Ojo OA, et al. Nat Commun. 2025 May 15;16(1):4542. doi: 10.1038/s41467-025-59784-1. Nat Commun. 2025. PMID: 40374625 Free PMC article.
Gfi1-Foxo1 axis controls the fidelity of effector gene expression and developmental maturation of thymocytes.
Shi LZ, Saravia J, Zeng H, Kalupahana NS, Guy CS, Neale G, Chi H. Shi LZ, et al. Proc Natl Acad Sci U S A. 2017 Jan 3;114(1):E67-E74. doi: 10.1073/pnas.1617669114. Epub 2016 Dec 19. Proc Natl Acad Sci U S A. 2017. PMID: 27994150 Free PMC article.

References

1. Josefowicz SZ, et al. Annu Rev Immunol. 2012;30:531–64. doi: 10.1146/annurev.immunol.25.022106.141623. - DOI - PMC - PubMed
1. Hsieh CS, et al. Nat Rev Immunol. 2012;12:157–67. - PubMed
1. Ohkura N, et al. Immunity. 2012;37:785–99. doi: 10.1016/j.immuni.2012.09.010. - DOI - PubMed
1. Cheng G, et al. J Immunol. 2013;190:1567–75. doi: 10.4049/jimmunol.1201218. - DOI - PMC - PubMed
1. Yücel R, et al. J Exp Med. 2003;197:831–44. doi: 10.1084/jem.20021417. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Research Materials
- NCI CPTC Antibody Characterization Program